



Atty. Docket No.: 5538/1010

PATENT

TECH CENTER 1600 2900

RECEIVED

JUN 11 2002

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kay and Larche
Serial No.: 09/610,134
Filed: July 5, 2000
Entitled: "Methods and Compositions for
Desensitisation"


Examiner: DeCloux, A.
Group Art Unit: 1644
Conf. No.:

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, **Express Mail Label No. EV097553265US** on this date, **May 28, 2002**, postage prepaid, in an envelope addressed to U.S. Patent and Trademark Office, 2011 South Clark Place, Customer Window, Box Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, Virginia 22202.

Mark Fitzgerald

Name of Person Mailing Paper


Signature of Person Mailing Paper

U.S. Patent and Trademark Office
2011 South Clark Place, Customer Window
Box Sequence
Crystal Plaza Two, Lobby Room 1B03
Arlington, Virginia 22202

TRANSMITTAL LETTER


Enclosed for filing in the above-identified patent application, please find the following documents:

1. Response to Office Action mailed March 26, 2002;
2. Marked-Up Version of page 39;
3. Petition for Extension of Time; and
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge all fees to Deposit Account No. 16-0085, Reference No. 5538/1010. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: May 28, 2002


Name: Kathleen M. Williams

Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617 229 6100



Express Mail Label No.: EV097553265US

Date of Deposit: May 28, 2002

Atty. Docket No.: 5538/1010

PATENT

TECH CENTER 1600 2900

JUN 11 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Kay and Larche
Serial No.:	09/610,134
Filed:	July 5, 2000
Entitled:	"Methods and Compositions for Desensitisation"

Examiner: DeCloux, A.

Group Art Unit: 1644

Conf. No.:

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

RESPONSE TO OFFICE COMMUNICATION

Sir:

This is a response to the Office communication mailed on March 26, 2002. The Office communication states that the above referenced application contains sequences without sequence ID NO: tags. Specifically, sequences without SEQ ID tags are disclosed in the specification, i.e., on page 39, lines 8, 14, 22 and 30.

Applicants submit that there are two sequences disclosed on page 39: FC1P3 and FC1P2, which have been assigned SEQ ID NO. 3 and 2 respectively. These two sequences were listed in the previously filed CRF and paper copy of the sequence listing of the instant application, therefore, no new CRF and paper copy of the sequence listing are required according to the instructions in the Office communication.

Applicants kindly request the following amendment to be entered to the specification of the instant application:

Please delete the paragraph at page 38, line 29, to page 39, line 9, and replace it with the

Figure 1. Murine T cells expressing two DRB1 variants, DRB1*1301 and *1302 are incubated overnight with each of the three FC1P peptides, or a control peptide, or medium alone. Cells are washed and incubated for one hour with cytostatic agent to prevent proliferation in the subsequent assay. T cells are then incubated for 48 hours with cells from a murine T cell line (J.1638) whole cat dander (and including the Fel d 1 protein). Proliferation of the T cells is measured by

their incorporation of the radiolabelled compound ³H-thymidine. T cells demonstrate a statistically significant response to the DR13 L cells and peptide FC1P3 (SEQ ID NO. 3) (KALPVVLENARILNCV) but not to the other peptides/control.- -

Please delete the paragraph at page 39, line 10 to line 15, and replace it with the following replacement paragraph:

- -Figure 4. Human fibroblasts expressing the DR1 allele DRB1*0101 are incubated overnight with each of the three FC1P peptides, or medium alone, as described for Figure 3. In T cell proliferation assays, T cells demonstrate a statistically significant response to the DR1 expressing cells and peptide FC1P3 (SEQ ID NO. 3) (KALPVVLENARILNCV) but not to the other peptides/control.- -

Please delete the paragraph at page 39, line 17 to line 23, and replace it with the following replacement paragraph:

- -Figure 5. Human fibroblasts expressing the DR4 alleles DRB1*0404 and DRB1*0405 are incubated overnight with each of the three FC1P SEQ ID NO. 2 peptides, or medium alone, as described for Figure 3. Figure 5 a) and b): in T cell proliferation assays, DRB1*0408 responder cells demonstrate a statistically significant response to the DRB1*0405 expressing cells and peptide FC1P2 (SEQ ID NO. 2) (EQVAQYKALPVVLENA) but not to DRB1*0404 expressing cells and peptide FC1P2 or to the other peptides/control.- -

Please delete the paragraph at page 39, line 25 to line 30, and replace it with the following replacement paragraph:

- -Figure 6. Human fibroblasts expressing the DR4 allele DRB1*0405 are incubated overnight with each of the three FC1P peptides, or medium alone, as described for Figure 3. In T cell proliferation assays, DRB1*0405 responder cells demonstrate a statistically significant response to the DRB1*0405 expressing cells and peptide FC1P2 (SEQ ID NO. 2)

A marked-up version showing the changes is attached

Applicants submit that, as required by 37 C.F.R. §1.821 (g), that the enclosed submission includes no new matter.

Date: May 1, 2002

Respectfully submitted,

Kathleen M. Williams
Name: Kathleen M. Williams

Registration No.: 34,380

Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100